Q-omics provides the consensus-scored GUSB profile across patient tissues and cancer cell-line models. GUSB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GUSB is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GUSB RNA expression shows 18,709 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where GUSB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSB survival associations across molecular data types. GUSB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSB RNA expression–survival associations across cancer types. High GUSB expression shows unfavorable associations in UVM, ACC, LGG, THCA and CESC, but favorable associations in THYM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GUSB RNA expression.
This table summarizes GUSB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GUSB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSB shows higher tumor expression in KIRC, HNSC, KIRP, COAD, STAD and BLCA. The KIRC box plot shows higher GUSB RNA expression in tumor versus normal tissue (log2 FC = +0.905, t-test p < 0.001).
This table shows molecular features associated with GUSB in patient tissues and cancer cell lines. In patient samples, GUSB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GUSB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
